Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial

Nakwon Kwak, Doosoo Jeon, Youngmok Park, Young Ae Kang, Kyung Jong Kim, Young Ran Kim, Byoung Soo Kwon, Yong-Soo Kwon, Hyung-Jun Kim, Jae Ho Lee, Ji Yeon Lee, Jung-Kyu Lee, Jeongha Mok, Minkyoung Cheon, Jiwon Park, Seokyung Hahn, Jae-Joon Yim, Nakwon Kwak, Doosoo Jeon, Youngmok Park, Young Ae Kang, Kyung Jong Kim, Young Ran Kim, Byoung Soo Kwon, Yong-Soo Kwon, Hyung-Jun Kim, Jae Ho Lee, Ji Yeon Lee, Jung-Kyu Lee, Jeongha Mok, Minkyoung Cheon, Jiwon Park, Seokyung Hahn, Jae-Joon Yim

Abstract

Background: The standard treatment regimen for drug-sensitive tuberculosis (TB), comprising four companion drugs, requires a minimum duration of 6 months, and this lengthy treatment leads to poor adherence and increased toxicity. To improve rates of adherence, reduce adverse events, and lower costs, a simplified and shortened treatment regimen is warranted.

Methods: This study is a multicenter, open-label randomized clinical trial of non-inferiority design that compares a new regimen with the conventional regimen for drug-sensitive pulmonary TB. The investigational group will use a regimen of high-dose rifampicin (30 mg/kg/day) with isoniazid and pyrazinamide, and the treatment will be maintained for 12 weeks after the achievement of negative conversion of sputum culture. The control group will be treated for 6 months with a World Health Organization-endorsed regimen consisting of isoniazid, rifampicin (10 mg/kg/day), ethambutol, and pyrazinamide. The primary endpoint is the proportion of unfavorable outcomes at 18 months after randomization. Secondary outcomes include time to unfavorable treatment outcome, time to culture conversion on liquid medium, treatment success rate at the end of treatment, proportion of recurrence at 18 months after randomization, time to recurrence after treatment completion, and adverse events of grade 3 or higher during the treatment. We predict a 10% unfavorable outcome for the control group, and 0% difference from the investigational group. Based on 80% verification power and a 2.5% one-sided significance level for a non-inferiority margin of 6%, 393 participants per group are required. Considering the 15% dropout rate, a total of 926 participants (463 in each group) will be recruited.

Discussion: This study will inform on the feasibility of the treatment regimen using high-dose rifampicin with a shortened and individualized treatment duration for pulmonary TB.

Trial registration: ClinicalTrials.gov NCT04485156 . Registered on July 24, 2020.

Keywords: Rifampicin; Shorter regimen; Tuberculosis.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study overview

References

    1. World Health Organization. Global tuberculosis report 2021.
    1. Korea Disease Control and Prevention Agency . Annual Report on the Notified Tuberculosis in Korea. 2021.
    1. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10):S231–S279.
    1. World Health Organization . Guidelines for treatment of drug-sensitive tuberculosis and patient care. 2017.
    1. Birch S, Govender V, Fried J, Eyles J, Daries V, Moshabela M, et al. Does treatment collection and observation each day keep the patient away? an analysis of the determinants of adherence among patients with Tuberculosis in South Africa. Health Policy Plan. 2016;31(4):454–461. doi: 10.1093/heapol/czv084.
    1. Dorman SE, Nahid P, Kurbatova EV, Phillips PP, Bryant K, Dooley KE, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705–1718. doi: 10.1056/NEJMoa2033400.
    1. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–1587. doi: 10.1056/NEJMoa1407426.
    1. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371:1599–1608. doi: 10.1056/NEJMoa1314210.
    1. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med. 2014;371(17):1588–1598. doi: 10.1056/NEJMoa1315817.
    1. Steingart K, Jotblad S, Robsky K, Deck D, Hopewell P, Huang D, et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2011;15(3):305–316.
    1. Boeree MJ, Diacon AH, Dawson R, Narunsky K, Du Bois J, Venter A, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191(9):1058–1065. doi: 10.1164/rccm.201407-1264OC.
    1. Svensson EM, Svensson RJ, Te Brake LH, Boeree MJ, Heinrich N, Konsten S, et al. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis. Clin Infect Dis. 2018;67(1):34–41. doi: 10.1093/cid/ciy026.
    1. Van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, van Plemper Balen G, et al. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis. 2011;52(9):e194–e9. doi: 10.1093/cid/cir184.
    1. Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17(1):39–49. doi: 10.1016/S1473-3099(16)30274-2.
    1. Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sanchez Garavito E, et al. Efficacy and safety of high-dose rifampin in pulmonary tuberculosis A randomized controlled trial. Am J Respir Crit Care Med. 2018;198(5):657–66. doi: 10.1164/rccm.201712-2524OC.
    1. Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, van Ingen J, Kuipers S, et al. High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre. PLoS ONE. 2019;14(3):e0213718. doi: 10.1371/journal.pone.0213718.
    1. Korea Disease Control and Prevention Agency. Korean Guidelines for Tuberculosis, 4th edition. 2020.
    1. World Health Organization. Definitions and reporting framework for tuberculosis–2013 revision: updated December 2014 and January 2020.
    1. International Council For Harmonization Of Technical Requirement For Pharmaceuticals For Human Use (ICH). ICH harmonised guideline. Integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). 2016.
    1. Common Terminology Criteria for Adverse Events (CTCAE). Bethesda, MD: National Institutes of Health, 2010.
    1. Kim J, Kwak N, Lee HY, Kim TS, Kim C-K, Han SK, et al. Effect of drug resistance on negative conversion of sputum culture in patients with pulmonary tuberculosis. Int J Infect Dis. 2016;42:64–68. doi: 10.1016/j.ijid.2015.11.018.
    1. Lee J-K, Lee JY, Kim DK, Yoon HI, Jeong I, Heo EY, et al. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. Lancet Infect Dis. 2019;19(1):46–55. doi: 10.1016/S1473-3099(18)30480-8.
    1. Yu S, Sohn H, Kim H-Y, Kim H, Oh K-H, Kim H-J, et al. Evaluating the impact of the nationwide public–private mix (PPM) program for tuberculosis under National Health Insurance in South Korea: a difference in differences analysis. PLoS Med. 2021;18(7):e1003717. doi: 10.1371/journal.pmed.1003717.
    1. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007;51(11):3781–3788. doi: 10.1128/AAC.01533-06.
    1. Hu Y, Liu A, Ortega-Muro F, Alameda-Martin L, Mitchison D, Coates A. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo. Front Microbiol. 2015;6:641.
    1. Jayaram R, Gaonkar S, Kaur P, Suresh B, Mahesh B, Jayashree R, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003;47(7):2118–2124. doi: 10.1128/AAC.47.7.2118-2124.2003.
    1. Svensson RJ, Svensson EM, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, et al. Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations. J Infect Dis. 2018;218(6):991–999. doi: 10.1093/infdis/jiy242.
    1. Shepardson D, MacKenzie WR. Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices. Int J Tuberc Lung Dis. 2014;18(6):751. doi: 10.5588/ijtld.14.0052.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する